Pablo B. Nery
YOU?
Author Swipe
View article: Contemporary outcomes of implantable cardioverter defibrillator patients on amiodarone
Contemporary outcomes of implantable cardioverter defibrillator patients on amiodarone Open
Background Patients with implantable cardioverter defibrillators (ICDs) frequently experience shocks due to arrhythmias. Current treatment options include ventricular tachycardia (VT) ablation, clinical follow-up, and antiarrhythmic medica…
View article: Effectiveness of a Standardized Approach to Repeat Paroxysmal Atrial Fibrillation Ablation: Insights Into the Value of Extrapulmonary Vein Targets
Effectiveness of a Standardized Approach to Repeat Paroxysmal Atrial Fibrillation Ablation: Insights Into the Value of Extrapulmonary Vein Targets Open
A comprehensive protocol for repeat PAF ablation resulted in arrhythmia-free survival at 1 year in 53% of patients. Durably isolated PVs were observed in 26.5% of cases. None of the ablation protocol's steps was suggested to independently …
View article: Safety and Efficacy of Stereotactic Cardiac Radio-Ablation for Ventricular Tachycardia in Patients at High Risk of Mortality
Safety and Efficacy of Stereotactic Cardiac Radio-Ablation for Ventricular Tachycardia in Patients at High Risk of Mortality Open
Noninvasive stereotactic CRA is well tolerated with good short-term efficacy for recurrent VT on a "compassionate use" basis. Prospective randomized controlled trials to determine the relative efficacy of CA vs CRA for VT are urgently requ…
View article: Report of cardiac electronic device implant complications over a 7-year study period
Report of cardiac electronic device implant complications over a 7-year study period Open
Background The global placement of cardiac implantable electronic devices (CIEDs) is on the rise. Complications linked to device implantation present a substantial burden on healthcare systems and patients alike. It is imperative to compre…
View article: High‐power short‐duration versus low‐power long‐duration ablation for pulmonary vein isolation: A substudy of the AWARE randomized controlled trial
High‐power short‐duration versus low‐power long‐duration ablation for pulmonary vein isolation: A substudy of the AWARE randomized controlled trial Open
Introduction Pulmonary vein isolations (PVI) are being performed using a high‐power, short‐duration (HPSD) strategy. The purpose of this study was to compare the clinical efficacy and safety outcomes of an HPSD versus low‐power, long‐durat…
View article: High-Power Short-Duration vs Low-Power Long-Duration Ablation for Pulmonary Vein Isolation: A Substudy of the AWARE Randomized Controlled Trial
High-Power Short-Duration vs Low-Power Long-Duration Ablation for Pulmonary Vein Isolation: A Substudy of the AWARE Randomized Controlled Trial Open
Background Pulmonary vein isolations (PVI) are being performed using a high-power, short duration (HPSD) strategy. The purpose of this study was to compare the clinical efficacy and safety outcomes of a HPSD vs low-power long duration (LPL…
View article: Incidence of Atrial Fibrillation as the Initial Manifestation of Cardiac Sarcoidosis: Insights From a Catheter Ablation Registry
Incidence of Atrial Fibrillation as the Initial Manifestation of Cardiac Sarcoidosis: Insights From a Catheter Ablation Registry Open
CS is a rare finding among patients undergoing a first-time AF ablation. Our findings suggest that AF is an uncommon initial presentation of CS. Thus, investigations for CS in patients with AF are not warranted routinely, unless additional…
View article: Investigating the treatment phenotypes of cardiac sarcoidosis: A prospective cohort study
Investigating the treatment phenotypes of cardiac sarcoidosis: A prospective cohort study Open
The initial response rate to prednisone was high with all patients showing a reduction in FDG uptake and 19/21 meeting a PET definition of >25 % response. Secondly, a trial of therapy discontinuation was able to classify 7/19 patients as a…
View article: Should they stay, or should they go: Do we need to remove the old cardiac implantable electronic device if a new system is required on the contralateral side?
Should they stay, or should they go: Do we need to remove the old cardiac implantable electronic device if a new system is required on the contralateral side? Open
In patients requiring new CIED implant on the contralateral side, abandoning the old device is feasible. This approach may reduce the risk of infection and concerns regarding abandoned leads and magnetic resonance imaging scans. Knowledge …
View article: Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review
Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review Open
Background Corticosteroid therapy for the treatment of clinically manifest cardiac sarcoidosis is generally recommended. Our group previously systematically reviewed the data in 2013; since then, there has been increasing quality and quant…
View article: Remote-only monitoring for patients with cardiac implantable electronic devices: a before-and-after pilot study
Remote-only monitoring for patients with cardiac implantable electronic devices: a before-and-after pilot study Open
ClinicalTrials.gov, no. NCT02585817.
View article: Differences in Healthcare Use Between Patients With Persistent and Paroxysmal Atrial Fibrillation Undergoing Catheter‐Based Atrial Fibrillation Ablation: A Population‐Based Cohort Study From Ontario, Canada
Differences in Healthcare Use Between Patients With Persistent and Paroxysmal Atrial Fibrillation Undergoing Catheter‐Based Atrial Fibrillation Ablation: A Population‐Based Cohort Study From Ontario, Canada Open
Background Patients with persistent atrial fibrillation (AF) undergoing catheter‐based AF ablation have lower success rates than those with paroxysmal AF. We compared healthcare use and clinical outcomes between patients according to their…
View article: FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: A prospective study with comparison to FDG-PET
FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: A prospective study with comparison to FDG-PET Open
BACKGROUND:2-deoxy-2-[18F]fluoro-D-glucose’s (FDG) biodistribution limits the evaluation of cardiac sarcoidosis (CS) and neurosarcoidosis (NS). While protocols for cardiac suppression exist, they can be inconvenient for patients and lead t…
View article: FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET
FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET Open
Background 2-deoxy-2-[18F]fluoro- d -glucose’s (FDG) biodistribution limits the evaluation of cardiac sarcoidosis (CS) and neurosarcoidosis (NS). While protocols for cardiac suppression exist, they can be inconvenient for patients and lead…